Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 7 (4) , 153-157
- https://doi.org/10.1016/s1078-1439(02)00182-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancerCancer Chemotherapy and Pharmacology, 2000
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyJournal of Clinical Oncology, 2000
- Progress in the Management of Metastatic Bladder CancerCancer Control, 2000
- Gemcitabine in locally advanced and/or metastatic bladder cancerCritical Reviews in Oncology/Hematology, 2000
- Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial CancerJournal of Clinical Oncology, 2000
- Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trialAnnals of Oncology, 1999
- Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of TherapyJournal of Clinical Oncology, 1999
- Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 1999
- Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell CarcinomaJournal of Clinical Oncology, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958